Alvotech - ALVO
About Gravity Analytica
Recent News
- 11.13.2025 - Q3 2025 Earnings
- 11.12.2025 - Publishing of Q3 results, after the close of the US market.
- 10.06.2025 - European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
- 09.22.2025 - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
- 09.22.2025 - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
- 09.19.2025 - Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
- 09.10.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference New York
- 09.04.2025 - Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
- 08.22.2025 - Analyst_Arvid_Necander_DNBCarnegie
- 08.21.2025 - Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®